The most frequent mechanism of acquired resistance to first- and second-generation EGFR-TKIs in EGFR-mutated lung cancer is the presence of an EGFR T790M mutation in exon 20 and confers sensitivity to third-generation inhibitors [18,19]. The gene discussed is EGFR; the disease is lung cancer.